Investment
Features
FeesSafety
Academy
More
Pluang+

Compare TransMedics Group Inc (TMDX) vs YieldMax TSLA Option Income Strategy ETF (TSLY) Price & Performance

TransMedics Group IncTrade
YieldMax TSLA Option Income Strategy ETFTrade

Price performance (Past 24H)

Key statistics

TransMedics Group Inc vs YieldMax TSLA Option Income Strategy ETF — how do they compare? TransMedics Group Inc trades at $87.17 (market cap $3.10B), while YieldMax TSLA Option Income Strategy ETF trades at $21.51. The key difference: TransMedics Group Inc is trading nearer its 52-week high, YieldMax TSLA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.

TMDXTSLY
Market Cap
$3.10B
Sector
TechnologyIncome / Options Overlay
52-Week High
$150.42$48.25
52-Week Low
$61.99$20.49
Enterprise Value
$3.49B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

TransMedics Group Inc

TransMedics Group (TMDX) trades at $86.43, down 2.24% amid recent earnings misses but maintains strong analyst support with a $99.57 consensus target. The stock shows bullish technical signals with support at $84-87, though RSI levels suggest overbought conditions. Fundamentally, the company demonstrates robust profitability with 58.69% gross margins and 22.69% net income margins, despite recent quarterly earnings falling short of expectations.

Investment outlook remains positive given strong institutional backing and growth potential in organ transplant technology, though risks include ongoing fiduciary investigations and margin pressure from increased operating costs. The stock offers 15% upside to consensus targets but requires monitoring of Q3 earnings performance and legal developments.

YieldMax TSLA Option Income Strategy ETF

TSLY trades at $21.51, down 1.01% today, with a bearish technical signal from moving averages and mixed oscillators. The ETF generates high income through weekly distributions, but faces capped upside due to its covered call strategy on Tesla. Recent news highlights concerns over missed Tesla rallies and reduced upside capture, while distributions remain consistent, averaging around $0.28 per share recently.

Outlook is cautious due to structural limitations in capturing Tesla's gains, presenting income opportunity but significant growth risk. Investors face volatility from Tesla's performance and potential return of capital in distributions, warranting careful assessment of income versus capital appreciation goals.

Returns comparison

Trailing returns across standard periods

About TransMedics Group Inc

TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.

Read more on TMDX

About YieldMax TSLA Option Income Strategy ETF

TSLY is an actively managed ETF that seeks to provide high monthly income by employing a synthetic covered call strategy on Tesla, Inc. (TSLA). It does not own Tesla stock directly; instead, it uses a combination of call and put options to simulate long exposure while simultaneously selling call options to collect premiums. It is designed for income-focused investors who are willing to trade TSLA's potential upside for immediate, aggressive yield.

Read more on TSLY